Healthcare Moves Home: Who Captures Value
Healthcare is moving closer to the patient. The commercial question is who captures the value when it gets there.
GLP-1s are testing direct-to-patient access models. Biologics are being reformulated for subcutaneous and self-administered use. Pre-filled syringes, auto-injectors and wearable injectors are turning drug delivery into a strategic differentiator, while remote monitoring and decentralised trials are extending care, evidence generation and patient engagement beyond traditional clinical settings.
This month’s Market Watch examines how the consumerisation of healthcare is reshaping pharma strategy, drug delivery, clinical development and investment. The opportunity is not simply a better patient experience. It is a new operating model built around access, adherence, home-based care, real-world data and control of the patient relationship.
Visiongain Top Takeaways
- Competition is shifting from clinical access alone to convenience, trust, adherence and control of the care journey.
- GLP-1s are becoming the clearest test case for direct-to-patient pharma, as telehealth, online pharmacy and cash-pay routes reshape how high-value chronic therapies reach consumers.
- Self-administered biologics, pre-filled syringes and wearable injectors are turning drug delivery into a strategic battleground, not a packaging or administration detail.
- Remote monitoring is becoming the evidence and safety layer behind home-based care, helping companies track outcomes, support adherence and strengthen payer conversations.
- The strongest models will connect therapy, delivery, data, patient services and governance without weakening clinical trust.
Weight-Loss Therapies: The Consumer Drug Arrives
No therapy class has pushed healthcare consumerisation into public view more forcefully than GLP-1 receptor agonists.
Semaglutide and tirzepatide, marketed through brands including Ozempic, Wegovy, Mounjaro and Zepbound, have moved from specialist diabetes and obesity care into mainstream demand at unusual speed. They are now part of a wider commercial debate around access, affordability, online prescribing, employer coverage, cash-pay demand and long-term adherence.
Visiongain forecasts the global anti-obesity drugs market to expand from US$22.52bn in 2026 to US$195.99bn by 2036, at a CAGR of 24.2%. That growth positions weight-management therapies as one of pharma’s clearest examples of patient demand becoming a major long-term commercial market.
The access model is changing too. LillyDirect, NovoCare Pharmacy, WeightWatchers, Hims & Hers and LifeMD show how the prescription-to-patient journey is being shortened, with faster access, fewer clinic barriers and more digitally supported fulfilment.
The commercial implications go beyond convenience. Direct and digitally enabled routes can help capture demand, improve engagement, strengthen adherence and defend brand position where payer coverage remains uneven.
Visiongain Insight: GLP-1s are becoming pharma’s clearest test case for consumer-facing chronic disease. Effective drugs will not be enough on their own; sustained value will also depend on access routes, affordability strategies and patient-support models that can hold demand over years, not months.
Self-Administered Biologics: Specialist Treatment Moves Closer to Home
Biologics were once closely tied to infusion centres, specialist supervision and scheduled clinic visits. That model is beginning to loosen.
Subcutaneous formulations, auto-injectors and wearable injectors are shifting more biologic treatment into lower-burden settings. In immunology, therapies such as adalimumab, secukinumab and dupilumab have shown how at-home use can become routine in chronic disease. In more complex areas, including oncology, haematology and rare disease, the shift is more nuanced. The opportunity is not always full self-injection at home. In some cases, it is shorter clinic visits, lower nursing burden and more flexible care pathways.
Merck’s Keytruda Qlex, Roche’s subcutaneous cancer therapy portfolio and emicizumab in haemophilia A all point to the same strategic change: delivery format is becoming part of competitive positioning, not a back-end technical detail.
Visiongain estimates that the global biologics market will reach US$1,127.0bn by 2035, at a CAGR of 8.5%. As biologics move further into chronic, specialist and high-value treatment areas, products that reduce treatment burden and fit more easily into patients’ lives will be better placed to compete on adherence, access, capacity relief and long-term value.
Visiongain Insight: Self-administration is becoming a lifecycle management strategy. For biologics companies, subcutaneous formats, auto-injectors and home-compatible delivery can protect share, improve adherence and strengthen differentiation as biosimilar competition intensifies.
Pre-Filled Syringes: Where Packaging Becomes Product Strategy
Pre-filled syringes are emerging as a key enabling technology behind lower-burden and home-based care.
Once treated largely as a packaging format, they are now central to biologics, vaccines and high-value injectable therapies because they combine dose accuracy, sterility, usability and convenience.
Visiongain values the global Pre-Filled Syringes Market at US$9.21bn in 2026 and forecasts it to reach US$22.18bn by 2036, at a CAGR of 9.2%. Growth is being driven by biologic pipeline expansion, self-administration, auto-injector adoption and the rise of combination products.
For pharma, CDMOs, device partners and packaging specialists, value is shifting beyond fill-finish into drug-device integration, formulation compatibility, human factors, material selection and regulatory execution. Device choice can influence adherence, patient confidence, product differentiation and lifecycle strategy.
Visiongain Insight: As more injectable therapies move beyond traditional clinical settings, the delivery system is becoming part of the product’s competitive value. Companies that can combine formulation, fill-finish, device design, usability and regulatory expertise will be better placed to capture margin and extend product lifecycles.
Home Treatment: The Hospital Without Walls
Hospital-at-home is no longer just a pandemic workaround. Supported by reimbursement, remote monitoring and pressure on inpatient capacity, it is becoming a more established care model.
Visiongain estimates that the global home healthcare market will grow from US$412.2bn in 2025 to US$989.6bn by 2035, at a CAGR of 9.2%. That expansion reflects ageing populations, chronic disease and the push to manage more treatment in lower-cost, lower-friction settings.
In oncology and chronic disease, ambulatory infusion pumps, home nursing, oral therapies, subcutaneous formulations and remote monitoring are expanding what can be managed outside hospital. But the opportunity depends on logistics, reimbursement, patient education, nursing capacity, clinical governance and clear escalation pathways.
This changes the development brief. Products designed only for the clinic may lose ground to those built for administration, monitoring and follow-up wherever care is delivered.
Visiongain Insight: Home treatment is becoming a commercial design requirement. Companies that build administration, monitoring, reimbursement and follow-up into launch planning will be better placed to scale beyond the hospital.
Digital Monitoring: Closing the Loop
Treatment cannot move further into the home without a reliable way to monitor patients outside the clinic.
Wearables, connected diagnostics, mobile health apps and remote patient monitoring platforms are becoming the data infrastructure behind distributed care, supporting earlier intervention, adherence tracking, payer evidence and more personalised patient support.
Continuous glucose monitors from Dexcom, Abbott and Medtronic have shown what remote monitoring can look like at scale. Similar models are now extending across cardiovascular disease, oncology, neurology and respiratory medicine through cardiac monitors, electronic patient-reported outcomes, seizure detection wearables and smart inhalers.
The challenge is not collecting more patient data. It is turning that data into trusted, clinically useful evidence that can support care pathways, reimbursement models and product strategy.
Visiongain Insight: Digital monitoring provides the infrastructure that makes distributed care safer and more measurable.Competitive advantage will sit with companies that can convert patient-generated data into clinical confidence, payer value and stronger long-term engagement.
Decentralised Trials: Research Follows the Patient
The same forces reshaping care delivery are changing clinical development.
Decentralised and hybrid trial models shift selected activities away from central trial sites through remote visits, local healthcare providers, home nursing, digital monitoring and electronic patient-reported outcomes. For sponsors and CROs, the appeal is practical: faster recruitment, better retention, wider reach and less dependence on overloaded trial sites.
Visiongain forecasts the global Decentralised Clinical Trials Market to grow from US$11.3bn in 2026 to US$33.5bn by 2036, at a CAGR of 11.5%. That growth reflects a shift from site convenience alone towards patient access, data continuity and trial resilience.
Visiongain Insight: Decentralised trials are becoming part of pharma’s access strategy, not just its research operations. Sponsors and CROs that can widen participation without weakening oversight, data quality or patient safety will be better placed to benefit.
Market Outlook
Taken together, GLP-1 access models, self-administered biologics, pre-filled syringes, home treatment, digital monitoring and decentralised trials point to a larger restructuring of healthcare.
More care is being delivered, monitored, supported and studied outside conventional settings. The patient is becoming a more active point of access, evidence generation and commercial decision-making, while hospitals, physicians, payers and established channels are being reorganised around a more distributed model.
Drug developers will need to factor usability, adherence and evidence generation into the product lifecycle earlier. CDMOs, device companies and digital health partners will be pulled towards integrated capabilities across formulation, fill-finish, delivery systems, monitoring and data. CROs will face rising demand for hybrid trial infrastructure that widens participation without weakening trial quality.
The shift carries real upside, but it raises the execution bar. Consumerisation can reduce friction, improve access and support adherence only if it is backed by reimbursement, governance, interoperability and trust.
Healthcare has already moved closer to the patient. The strategic challenge is building commercial models that make that shift scalable, clinically robust and commercially defensible.
From Visiongain
The following reports examine markets where home-based care, self-administration, digital monitoring, decentralised research and real-world adoption are becoming central to commercial performance:
